Cover Image

Pembrolizumab for previously treated, microsatellite instability-high/mismatch repair-deficient advanced colorectal cancer: final analysis of KEYNOTE-164

Background - Pembrolizumab demonstrated durable clinical benefit and manageable safety in previously treated advanced or metastatic microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) colorectal cancer (CRC) in the phase 2 KEYNOTE-164 study. Results from the final analysis are p...

Full description

Saved in:
Bibliographic Details
Main Authors: Le, Dung T. (Author) , Diaz, Luis A. (Author) , Kim, Tae Won (Author) , Van Cutsem, Eric (Author) , Geva, Ravit (Author) , Jäger, Dirk (Author) , Hara, Hiroki (Author) , Burge, Matthew (Author) , O’Neil, Bert H. (Author) , Kavan, Petr (Author) , Yoshino, Takayuki (Author) , Guimbaud, Rosine (Author) , Taniguchi, Hiroya (Author) , Élez, Elena (Author) , Al-Batran, Salah-Eddin (Author) , Boland, Patrick M. (Author) , Cui, Yi (Author) , Leconte, Pierre (Author) , Marinello, Patricia (Author) , André, Thierry (Author)
Format: Article (Journal)
Language:English
Published: June 2023
In: European journal of cancer
Year: 2023, Volume: 186, Pages: 185-195
ISSN:1879-0852
DOI:10.1016/j.ejca.2023.02.016
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.ejca.2023.02.016
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0959804923001089
Get full text
Author Notes:Dung T. Le, Luis A. Diaz, Tae Won Kim, Eric Van Cutsem, Ravit Geva, Dirk Jäger, Hiroki Hara, Matthew Burge, Bert H. O’Neil, Petr Kavan, Takayuki Yoshino, Rosine Guimbaud, Hiroya Taniguchi, Elena Élez, Salah-Eddin Al-Batran, Patrick M. Boland, Yi Cui, Pierre Leconte, Patricia Marinello, Thierry André
Description
Summary:Background - Pembrolizumab demonstrated durable clinical benefit and manageable safety in previously treated advanced or metastatic microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) colorectal cancer (CRC) in the phase 2 KEYNOTE-164 study. Results from the final analysis are presented. - Methods - Eligible patients had unresectable or metastatic MSI-H/dMMR CRC and ≥2 prior systemic therapies (cohort A) or ≥1 prior systemic therapy (cohort B). Patients received pembrolizumab 200mg intravenously every 3 weeks for ≤35 cycles. The primary end-point was objective response rate (ORR) assessed per Response Evaluation Criteria in Solid Tumors, version 1.1 by blinded independent central review. Secondary end-points included duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety and tolerability. - Results - Sixty-one patients in cohort A and 63 patients in cohort B were enroled; median follow-up was 62.2 months and 54.4 months, respectively. ORR was 32.8% (95% CI, 21.3%-46.0%) in cohort A and 34.9% (95% CI, 23.3%-48.0%) in cohort B. Median DOR was not reached (NR) in either cohort. Median PFS was 2.3 months (95% CI, 2.1-8.1) in cohort A and 4.1 months (95% CI, 2.1-18.9) in cohort B. Median OS was 31.4 months (95% CI, 21.4-58.0) in cohort A and 47.0 months (95% CI, 19.2-NR) in cohort B. No new safety signals were observed. Nine patients who initially responded experienced disease progression off therapy and received second-course pembrolizumab. Six patients (66.7%) completed an additional 17 cycles of pembrolizumab, and 2 patients achieved a partial response. - Conclusions - Pembrolizumab continued to show durable antitumor activity, prolonged OS, and manageable safety in patients with previously treated MSI-H/dMMR CRC. - Clinical Trial Registry Information - ClinicalTrials.gov, NCT02460198
Item Description:Online verfügbar: 24. Februar 2023, Artikelversion: 2. Mai 2023
Gesehen am 16.08.2023
Physical Description:Online Resource
ISSN:1879-0852
DOI:10.1016/j.ejca.2023.02.016

Similar Items